NEWS FIRST NEEDLE-FREE NASAL SPRAY FOR ANAPHYLAXIS
People with severe allergies in the UK now have access to a needle-free alternative for treating anaphylaxis.
ALK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy®
, a ready-to-use adrenaline nasal
spray, for emergency use in adults and children weighing 30kg or more.
This approval marks a first-of-its-kind treatment for the UK delivering life-saving adrenaline without the need for an injection.
A Convenient, Non-Invasive Option EURneffy® offers a simple, non-invasive and portable alternative to traditional adrenaline auto-injectors. Designed for ease of use during emergencies, the nasal spray delivers a single, full dose of adrenaline when activated - no needles, no priming and no complicated instructions required.
Key features of EURneffy® include:
• Useful, convenient and easy to use, even in stressful situations
• Non-invasive – administered through the nose • 30-month shelf life • No special storage required, including resilience to freezing and heat
• Clinical performance comparable to adrenaline auto-injectors (AAIs) across a range of dosing conditions.
Dr Helen Evans-Howells, GP, allergy specialist and Chair of the Anaphylaxis UK Clinical and Scientific Panel, said, “We know that many
patients and carers delay or avoid using adrenaline auto-injectors due to fear, confusion or hesitancy. A nasal spray addresses these issues and could lead to quicker treatment and better outcomes. EURneffy®
gives doctors and
patients an important new option in managing severe allergies.”
Anaphylaxis requires fast action, but research shows many patients hesitate to use, or do not carry, their prescribed auto-injectors. By offering a needle-free, user-friendly alternative, EURneffy® aims to improve accessibility, usability, and adherence - making it easier for patients to act quickly in emergencies at home, school or work.
MHRA approval follows data from over 700 clinical trial participants, confirming EURneffy® rapidly absorbed, well tolerated and effective
is SIGNIFICANT INVESTMENT TO SUPPORT OBESITY IN SCOTLAND
Scotland’s community pharmacies are set to play a central role in a major new UK-wide obesity management initiative, following today’s announcement from the Department of Health and Social Care (DH).
The programme, backed by up to £85 million in combined government and pharmaceutical industry investment, will pilot new ways to support people living with obesity.
It will bring services directly into local settings such as pharmacies, digital platforms and community access points, with at least £10 million earmarked specifically for Scotland, Wales and Northern Ireland.
6
scotpharm.com
Under the plans, innovative services will begin as early as summer 2026 in participating areas.
Local clinicians will determine patient eligibility, while models must operate outside existing specialist weight management services to avoid overloading them. All services will be required to follow national guidelines, NHS governance and clinical standards.
Health Secretary Wes Streeting framed the initiative as a step change in tackling obesity, “We are determined to bring revolutionary modern care to everyone that needs it, not just those who can afford to pay. This collaboration will help patients living with obesity in a matter
of months through testing better access to weight loss services and treatments.”
The programme builds on a collaboration announced last October between the UK Government and Lilly, which could generate up to £279 million of investment. The government will contribute £50 million of new investment, while Lilly will provide £35 million in grant funding.
With dedicated funding for Scotland, this pilot presents an opportunity to further embed community pharmacy at the heart of public health delivery. It aligns closely with Scotland’s preventative care agenda and builds on the sector’s growing reputation as a trusted, accessible healthcare provider.
even when patients had nasal congestion or were self-administering.
The nasal spray demonstrated pharmacological outcomes comparable to auto-injectors, even during self-administration, repeat dosing and in paediatric use.
Dr Henriette Mersebach, Executive Vice President of R&D at ALK, added; “Our goal is to make adrenaline more accessible and easier to use for people living with severe allergies.”
EURneffy® is approved for the emergency
treatment of anaphylaxis caused by food, insect stings, medicines and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
